Source:http://linkedlifedata.com/resource/pubmed/id/11010838
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2000-12-1
|
| pubmed:abstractText |
A live-attenuated, intranasal respiratory syncytial virus (RSV) candidate vaccine, cpts-248/404, was tested in phase 1 trials in 114 children, including 37 1-2-month-old infants-a target age for RSV vaccines. The cpts-248/404 vaccine was infectious at 104 and 105 plaque-forming units in RSV-naive children and was broadly immunogenic in children >6 months old. Serum and nasal antibody responses in 1-2 month olds were restricted to IgA, had a dominant response to RSV G protein, and had no increase in neutralizing activity. Nevertheless, there was restricted virus shedding on challenge with a second vaccine dose and preliminary evidence for protection from symptomatic disease on natural reexposure. The cpts-248/404 vaccine candidate did not cause fever or lower respiratory tract illness. In the youngest infants, however, cpts-248/404 was unacceptable because of upper respiratory tract congestion associated with peak virus recovery. A live attenuated RSV vaccine for the youngest infant will use cpts-248/404 modified by additional attenuating mutations.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0022-1899
|
| pubmed:author |
pubmed-author:AndersonE LEL,
pubmed-author:BelsheR BRB,
pubmed-author:BoyceT GTG,
pubmed-author:CaseyRR,
pubmed-author:ChanockR MRM,
pubmed-author:CroweJ EJEJr,
pubmed-author:EichelbergerMM,
pubmed-author:HalburntL LLL,
pubmed-author:KarronR ARA,
pubmed-author:MurphyB RBR,
pubmed-author:RandolphV BVB,
pubmed-author:ReedG WGW,
pubmed-author:ThompsonJJ,
pubmed-author:ThumarBB,
pubmed-author:UdemS ASA,
pubmed-author:WhiteheadS SSS,
pubmed-author:WittekA EAE,
pubmed-author:WrightP FPF
|
| pubmed:issnType |
Print
|
| pubmed:volume |
182
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1331-42
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:11010838-Antibodies, Viral,
pubmed-meshheading:11010838-Breast Feeding,
pubmed-meshheading:11010838-Child, Preschool,
pubmed-meshheading:11010838-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:11010838-Humans,
pubmed-meshheading:11010838-Immunization,
pubmed-meshheading:11010838-Immunoglobulin A,
pubmed-meshheading:11010838-Infant,
pubmed-meshheading:11010838-Respiratory Syncytial Viruses,
pubmed-meshheading:11010838-Temperature,
pubmed-meshheading:11010838-Vaccines, Attenuated,
pubmed-meshheading:11010838-Viral Vaccines,
pubmed-meshheading:11010838-Virus Shedding
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.
|
| pubmed:affiliation |
Division of Infectious Disease, Dept. of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. peter.wright@mcmail.vanderbilt.edu
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|